Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma

Survival of activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL) is driven by chronic B cell receptor (BCR) signaling that activates the canonical NF-κB pathway. Inhibition of BTK by Ibrutinib has been shown to kill ABC DLBCL cells that carry activating mutations in the BCR adapto...

Full description

Bibliographic Details
Main Authors: Nagel, Daniel, Bognar, Miriam, Eitelhuber, Andrea C., Kutzner, Kerstin, Vincendeau, Michelle, Krappmann, Daniel
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747221/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747221/

Similar Items